Authors

Latest:

Dr. Krampitz on Therapeutic Targets in pNETs

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.

Geoffrey Lindeman, MD

Latest:

Dr. Lindeman on Rationale for a Phase Ib Trial of Venetoclax and Tamoxifen in Breast Cancer

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.

Geoffrey R. Oxnard, MD

Latest:

How Complementary Roles in Clinic and Industry Illuminate Avenues for Patient-Centered Cancer Care: With D. Ross Camidge, MD, PhD; and Geoff Oxnard, MD

Drs. Camidge and Oxnard discuss novel EGFR inhibitors, the role of precision medicine in early cancer detection, and balancing clinical and industry roles.

Geoffrey R. Oxnard, MD, Harvard

Geoffrey R. Oxnard, MD, Harvard Medical School

Geoffrey Sklar, MD

Latest:

Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.

Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital

Latest:

RP1: An Emerging Intratumoral Therapy

Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.

Geoffrey Uy, MD

Latest:

Dr. Uy on Therapy Selection in Acute Myeloid Leukemia

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).

Geoffrey Y. Ku, MD

Latest:

Dr. Ku on the Efficacy of Zanidatamab Plus Chemotherapy in HER2+ Gastroesophageal Adenocarcinoma

Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.

George Ansstas, MD

Latest:

Evolving Treatment Options for Older Patients with AML

About 13,300 new cases of acute myeloid leukemia (AML) are diagnosed yearly, and nearly 9,000 deaths occur in the United States.

George D. Demetri, MD

Latest:

Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

George D. Demetri, MD, Dana-Farber Cancer Center

George Demetri, MD

Latest:

Dr. Demetri Discusses Regorafenib for GIST Patients

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

George Kim, MD, 21st Century Oncology

George Kim, MD, University of Florida Health Oncology

George N. Ioannou, MD

Latest:

Dr. Ioannou on Treatment Options in Hepatocellular Carcinoma

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

George P. Kim, MD

Latest:

Dr. Kim on PRODIGE 37 in Pancreatic Cancer

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

George P. Kim, MD, 21st Century Oncology

George R. Blumenschein, MD

Latest:

Dr. Blumenschein on Immunotherapy Combinations in NSCLC

George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).

George R. Simon, MD

Latest:

Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.